vs
ADMA BIOLOGICS, INC.（ADMA）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.5倍（$212.2M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 18.8%，领先16.7%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 8.6%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 11.1%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
ADMA vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.5倍
$139.2M
营收增速更快
ADMA
高出9.8%
8.6%
净利率更高
ADMA
高出16.7%
18.8%
两年增速更快
ADMA
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $212.2M |
| 净利润 | $49.4M | $39.9M |
| 毛利率 | 63.8% | 71.9% |
| 营业利润率 | 45.1% | 18.6% |
| 净利率 | 35.5% | 18.8% |
| 营收同比 | 18.4% | 8.6% |
| 净利润同比 | -55.9% | 255.7% |
| 每股收益（稀释后） | $0.20 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARAMP
| Q4 25 | $139.2M | $212.2M | ||
| Q3 25 | $134.2M | $199.8M | ||
| Q2 25 | $122.0M | $194.8M | ||
| Q1 25 | $114.8M | $188.7M | ||
| Q4 24 | $117.5M | $195.4M | ||
| Q3 24 | $119.8M | $185.5M | ||
| Q2 24 | $107.2M | $176.0M | ||
| Q1 24 | $81.9M | $171.9M |
净利润ADMARAMP
| Q4 25 | $49.4M | $39.9M | ||
| Q3 25 | $36.4M | $27.4M | ||
| Q2 25 | $34.2M | $7.7M | ||
| Q1 25 | $26.9M | $-6.3M | ||
| Q4 24 | $111.9M | $11.2M | ||
| Q3 24 | $35.9M | $1.7M | ||
| Q2 24 | $32.1M | $-7.5M | ||
| Q1 24 | $17.8M | $-5.4M |
毛利率ADMARAMP
| Q4 25 | 63.8% | 71.9% | ||
| Q3 25 | 56.3% | 70.2% | ||
| Q2 25 | 55.1% | 70.1% | ||
| Q1 25 | 53.2% | 69.3% | ||
| Q4 24 | 53.9% | 71.9% | ||
| Q3 24 | 49.8% | 72.4% | ||
| Q2 24 | 53.6% | 70.6% | ||
| Q1 24 | 47.8% | 72.2% |
营业利润率ADMARAMP
| Q4 25 | 45.1% | 18.6% | ||
| Q3 25 | 38.0% | 10.7% | ||
| Q2 25 | 35.1% | 3.7% | ||
| Q1 25 | 30.4% | -6.1% | ||
| Q4 24 | 32.6% | 7.5% | ||
| Q3 24 | 33.1% | 4.0% | ||
| Q2 24 | 36.6% | -3.0% | ||
| Q1 24 | 26.7% | -8.3% |
净利率ADMARAMP
| Q4 25 | 35.5% | 18.8% | ||
| Q3 25 | 27.1% | 13.7% | ||
| Q2 25 | 28.1% | 4.0% | ||
| Q1 25 | 23.4% | -3.3% | ||
| Q4 24 | 95.2% | 5.7% | ||
| Q3 24 | 30.0% | 0.9% | ||
| Q2 24 | 29.9% | -4.3% | ||
| Q1 24 | 21.7% | -3.1% |
每股收益（稀释后）ADMARAMP
| Q4 25 | $0.20 | $0.62 | ||
| Q3 25 | $0.15 | $0.42 | ||
| Q2 25 | $0.14 | $0.12 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.45 | $0.17 | ||
| Q3 24 | $0.15 | $0.03 | ||
| Q2 24 | $0.13 | $-0.11 | ||
| Q1 24 | $0.08 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $403.4M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $962.3M |
| 总资产 | $624.2M | $1.3B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARAMP
| Q4 25 | $87.6M | $403.4M | ||
| Q3 25 | $61.4M | $376.9M | ||
| Q2 25 | $90.3M | $371.1M | ||
| Q1 25 | $71.6M | $420.8M | ||
| Q4 24 | $103.1M | $384.3M | ||
| Q3 24 | $86.7M | $348.4M | ||
| Q2 24 | $88.2M | $342.7M | ||
| Q1 24 | $45.3M | $368.9M |
总债务ADMARAMP
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARAMP
| Q4 25 | $477.3M | $962.3M | ||
| Q3 25 | $431.2M | $943.8M | ||
| Q2 25 | $398.3M | $947.8M | ||
| Q1 25 | $373.4M | $948.9M | ||
| Q4 24 | $349.0M | $957.7M | ||
| Q3 24 | $231.9M | $932.1M | ||
| Q2 24 | $188.3M | $951.9M | ||
| Q1 24 | $153.7M | $949.1M |
总资产ADMARAMP
| Q4 25 | $624.2M | $1.3B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.3B | ||
| Q4 24 | $488.7M | $1.3B | ||
| Q3 24 | $390.6M | $1.2B | ||
| Q2 24 | $376.4M | $1.2B | ||
| Q1 24 | $350.9M | $1.2B |
负债/权益比ADMARAMP
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | — |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | 0.1% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMARAMP
| Q4 25 | $35.6M | — | ||
| Q3 25 | $13.3M | $57.4M | ||
| Q2 25 | $21.1M | $-15.8M | ||
| Q1 25 | $-19.7M | — | ||
| Q4 24 | $50.2M | $45.1M | ||
| Q3 24 | $25.0M | $55.6M | ||
| Q2 24 | $45.6M | $-9.3M | ||
| Q1 24 | $-2.2M | — |
自由现金流ADMARAMP
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | $56.8M | ||
| Q2 25 | $18.7M | $-16.2M | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | $44.8M | ||
| Q3 24 | $24.0M | $55.4M | ||
| Q2 24 | $43.6M | $-9.6M | ||
| Q1 24 | $-4.6M | — |
自由现金流率ADMARAMP
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | 28.4% | ||
| Q2 25 | 15.3% | -8.3% | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | 22.9% | ||
| Q3 24 | 20.0% | 29.8% | ||
| Q2 24 | 40.7% | -5.4% | ||
| Q1 24 | -5.6% | — |
资本支出强度ADMARAMP
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.3% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.2% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | 1.0% |
现金转化率ADMARAMP
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 2.09× | ||
| Q2 25 | 0.62× | -2.04× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 4.02× | ||
| Q3 24 | 0.70× | 32.10× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RAMP
暂无分部数据
